CHK-IN-1 NEW
Price | $700 | $1800 |
Package | 1mg | 5mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-19 |
Product Details
Product Name: CHK-IN-1 | CAS No.: 1278405-51-8 |
Purity: 100% | Supply Ability: 10g |
Release date: 2024/11/19 |
Product Introduction
Bioactivity
Name | CHK-IN-1 |
Description | CHK-IN-1 is a dual inhibitor of CHK1 and CHK2 with antiproliferative activity. |
In vitro | CHK-IN-1, as per research findings, has the capability to prevent the DNA damage repair mechanism from causing cell cycle arrest at the G2/M checkpoint[1]. |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Keywords | CHKIN1 | CHK IN 1 | CHK-IN-1 |
Inhibitors Related | Rabusertib | CCT245737 | Prexasertib | PD0166285 | CHK1-IN-3 | CHK1-IN-4 hydrochloride | Prexasertib dihydrochloride | BX795 | ANI-7 | Baricitinib |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/5mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
$0.00/1KG |
VIP1Y
|
Shanghai Affida new material science and technology center
|
2024-05-06 | |
$34.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-15 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY